Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Reprogramming of fatty acid metabolism in cancer.

Koundouros N, Poulogiannis G.

Br J Cancer. 2020 Jan;122(1):4-22. doi: 10.1038/s41416-019-0650-z. Epub 2019 Dec 10. Review.

2.

Metabolic adaptability in metastatic breast cancer by AKR1B10-dependent balancing of glycolysis and fatty acid oxidation.

van Weverwijk A, Koundouros N, Iravani M, Ashenden M, Gao Q, Poulogiannis G, Jungwirth U, Isacke CM.

Nat Commun. 2019 Jun 20;10(1):2698. doi: 10.1038/s41467-019-10592-4.

3.

Nonsteroidal anti-inflammatory drugs and pain in cancer patients: a systematic review and reappraisal of the evidence.

Magee DJ, Jhanji S, Poulogiannis G, Farquhar-Smith P, Brown MRD.

Br J Anaesth. 2019 Aug;123(2):e412-e423. doi: 10.1016/j.bja.2019.02.028. Epub 2019 May 20.

4.

Phosphoinositide 3-Kinase/Akt Signaling and Redox Metabolism in Cancer.

Koundouros N, Poulogiannis G.

Front Oncol. 2018 May 15;8:160. doi: 10.3389/fonc.2018.00160. eCollection 2018. Review.

5.

Erratum: Asparagine bioavailability governs metastasis in a model of breast cancer.

Knott SRV, Wagenblast E, Khan S, Kim SY, Soto M, Wagner M, Turgeon MO, Fish L, Erard N, Gable AL, Maceli AR, Dickopf S, Papachristou EK, D'Santos CS, Carey LA, Wilkinson JE, Harrell JC, Perou CM, Goodarzi H, Poulogiannis G, Hannon GJ.

Nature. 2018 Apr 4;556(7699):135. doi: 10.1038/nature26162.

PMID:
29620732
6.

DNA Damage, Repair, and Cancer Metabolism.

Turgeon MO, Perry NJS, Poulogiannis G.

Front Oncol. 2018 Feb 5;8:15. doi: 10.3389/fonc.2018.00015. eCollection 2018. Review.

7.

Asparagine bioavailability governs metastasis in a model of breast cancer.

Knott SRV, Wagenblast E, Khan S, Kim SY, Soto M, Wagner M, Turgeon MO, Fish L, Erard N, Gable AL, Maceli AR, Dickopf S, Papachristou EK, D'Santos CS, Carey LA, Wilkinson JE, Harrell JC, Perou CM, Goodarzi H, Poulogiannis G, Hannon GJ.

Nature. 2018 Feb 15;554(7692):378-381. doi: 10.1038/nature25465. Epub 2018 Feb 7. Erratum in: Nature. 2018 Apr 4;556(7699):135.

8.

Perioperative events influence cancer recurrence risk after surgery.

Hiller JG, Perry NJ, Poulogiannis G, Riedel B, Sloan EK.

Nat Rev Clin Oncol. 2018 Apr;15(4):205-218. doi: 10.1038/nrclinonc.2017.194. Epub 2017 Dec 28. Review.

PMID:
29283170
9.

PARK2 loss promotes cancer progression via redox-mediated inactivation of PTEN.

Gupta A, Anjomani-Virmouni S, Koundouros N, Poulogiannis G.

Mol Cell Oncol. 2017 May 19;4(6):e1329692. doi: 10.1080/23723556.2017.1329692. eCollection 2017.

10.

Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance.

Martin LA, Ribas R, Simigdala N, Schuster E, Pancholi S, Tenev T, Gellert P, Buluwela L, Harrod A, Thornhill A, Nikitorowicz-Buniak J, Bhamra A, Turgeon MO, Poulogiannis G, Gao Q, Martins V, Hills M, Garcia-Murillas I, Fribbens C, Patani N, Li Z, Sikora MJ, Turner N, Zwart W, Oesterreich S, Carroll J, Ali S, Dowsett M.

Nat Commun. 2017 Nov 30;8(1):1865. doi: 10.1038/s41467-017-01864-y.

11.

Deconstructing the Metabolic Networks of Oncogenic Signaling Using Targeted Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS).

Poulogiannis G.

Methods Mol Biol. 2017;1636:405-414. doi: 10.1007/978-1-4939-7154-1_26.

PMID:
28730494
12.

PARK2 Depletion Connects Energy and Oxidative Stress to PI3K/Akt Activation via PTEN S-Nitrosylation.

Gupta A, Anjomani-Virmouni S, Koundouros N, Dimitriadi M, Choo-Wing R, Valle A, Zheng Y, Chiu YH, Agnihotri S, Zadeh G, Asara JM, Anastasiou D, Arends MJ, Cantley LC, Poulogiannis G.

Mol Cell. 2017 Mar 16;65(6):999-1013.e7. doi: 10.1016/j.molcel.2017.02.019.

13.

Proteomics profiling of interactome dynamics by colocalisation analysis (COLA).

Mardakheh FK, Sailem HZ, Kümper S, Tape CJ, McCully RR, Paul A, Anjomani-Virmouni S, Jørgensen C, Poulogiannis G, Marshall CJ, Bakal C.

Mol Biosyst. 2016 Dec 20;13(1):92-105.

14.

Decreased function of survival motor neuron protein impairs endocytic pathways.

Dimitriadi M, Derdowski A, Kalloo G, Maginnis MS, O'Hern P, Bliska B, Sorkaç A, Nguyen KC, Cook SJ, Poulogiannis G, Atwood WJ, Hall DH, Hart AC.

Proc Natl Acad Sci U S A. 2016 Jul 26;113(30):E4377-86. doi: 10.1073/pnas.1600015113. Epub 2016 Jul 11.

15.

Oncogenic KRAS Regulates Tumor Cell Signaling via Stromal Reciprocation.

Tape CJ, Ling S, Dimitriadi M, McMahon KM, Worboys JD, Leong HS, Norrie IC, Miller CJ, Poulogiannis G, Lauffenburger DA, Jørgensen C.

Cell. 2016 Jun 16;165(7):1818. doi: 10.1016/j.cell.2016.05.079. No abstract available.

16.

Oncogenic KRAS Regulates Tumor Cell Signaling via Stromal Reciprocation.

Tape CJ, Ling S, Dimitriadi M, McMahon KM, Worboys JD, Leong HS, Norrie IC, Miller CJ, Poulogiannis G, Lauffenburger DA, Jørgensen C.

Cell. 2016 May 5;165(4):910-20. doi: 10.1016/j.cell.2016.03.029. Epub 2016 Apr 14. Erratum in: Cell. 2016 Jun 16;165(7):1818.

17.

Loss of INPP4B causes a DNA repair defect through loss of BRCA1, ATM and ATR and can be targeted with PARP inhibitor treatment.

Ip LR, Poulogiannis G, Viciano FC, Sasaki J, Kofuji S, Spanswick VJ, Hochhauser D, Hartley JA, Sasaki T, Gewinner CA.

Oncotarget. 2015 Apr 30;6(12):10548-62.

18.

Wild-type K-ras has a tumour suppressor effect on carcinogen-induced murine colorectal adenoma formation.

Luo F, Poulogiannis G, Ye H, Hamoudi R, Dong G, Zhang W, Ibrahim AE, Arends MJ.

Int J Exp Pathol. 2014 Feb;95(1):8-15. doi: 10.1111/iep.12064. Epub 2013 Dec 20.

19.

Depletion of a putatively druggable class of phosphatidylinositol kinases inhibits growth of p53-null tumors.

Emerling BM, Hurov JB, Poulogiannis G, Tsukazawa KS, Choo-Wing R, Wulf GM, Bell EL, Shim HS, Lamia KA, Rameh LE, Bellinger G, Sasaki AT, Asara JM, Yuan X, Bullock A, Denicola GM, Song J, Brown V, Signoretti S, Cantley LC.

Cell. 2013 Nov 7;155(4):844-57. doi: 10.1016/j.cell.2013.09.057.

20.

The mTORC1 pathway stimulates glutamine metabolism and cell proliferation by repressing SIRT4.

Csibi A, Fendt SM, Li C, Poulogiannis G, Choo AY, Chapski DJ, Jeong SM, Dempsey JM, Parkhitko A, Morrison T, Henske EP, Haigis MC, Cantley LC, Stephanopoulos G, Yu J, Blenis J.

Cell. 2013 May 9;153(4):840-54. doi: 10.1016/j.cell.2013.04.023.

21.

IRS2 is a candidate driver oncogene on 13q34 in colorectal cancer.

Day E, Poulogiannis G, McCaughan F, Mulholland S, Arends MJ, Ibrahim AE, Dear PH.

Int J Exp Pathol. 2013 Jun;94(3):203-11. doi: 10.1111/iep.12021. Epub 2013 Apr 18.

22.

Identification of CDCP1 as a hypoxia-inducible factor 2α (HIF-2α) target gene that is associated with survival in clear cell renal cell carcinoma patients.

Emerling BM, Benes CH, Poulogiannis G, Bell EL, Courtney K, Liu H, Choo-Wing R, Bellinger G, Tsukazawa KS, Brown V, Signoretti S, Soltoff SP, Cantley LC.

Proc Natl Acad Sci U S A. 2013 Feb 26;110(9):3483-8. doi: 10.1073/pnas.1222435110. Epub 2013 Feb 1.

23.

Metabolic stress controls mTORC1 lysosomal localization and dimerization by regulating the TTT-RUVBL1/2 complex.

Kim SG, Hoffman GR, Poulogiannis G, Buel GR, Jang YJ, Lee KW, Kim BY, Erikson RL, Cantley LC, Choo AY, Blenis J.

Mol Cell. 2013 Jan 10;49(1):172-85. doi: 10.1016/j.molcel.2012.10.003. Epub 2012 Nov 8.

24.

Loss of RASSF1A synergizes with deregulated RUNX2 signaling in tumorigenesis.

van der Weyden L, Papaspyropoulos A, Poulogiannis G, Rust AG, Rashid M, Adams DJ, Arends MJ, O'Neill E.

Cancer Res. 2012 Aug 1;72(15):3817-3827. doi: 10.1158/0008-5472.CAN-11-3343. Epub 2012 Jun 18.

25.

Increased tumorigenesis associated with loss of the tumor suppressor gene Cadm1.

van der Weyden L, Arends MJ, Rust AG, Poulogiannis G, McIntyre RE, Adams DJ.

Mol Cancer. 2012 May 3;11:29. doi: 10.1186/1476-4598-11-29.

26.

Nuclear receptor binding protein 1 regulates intestinal progenitor cell homeostasis and tumour formation.

Wilson CH, Crombie C, van der Weyden L, Poulogiannis G, Rust AG, Pardo M, Gracia T, Yu L, Choudhary J, Poulin GB, McIntyre RE, Winton DJ, March HN, Arends MJ, Fraser AG, Adams DJ.

EMBO J. 2012 May 30;31(11):2486-97. doi: 10.1038/emboj.2012.91. Epub 2012 Apr 17.

27.

RAS signalling in the colorectum in health and disease.

Poulogiannis G, Luo F, Arends MJ.

Cell Commun Adhes. 2012 Feb;19(1):1-9. doi: 10.3109/15419061.2011.649380. Epub 2012 Jan 10. Review.

PMID:
22233291
28.

Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses.

Anastasiou D, Poulogiannis G, Asara JM, Boxer MB, Jiang JK, Shen M, Bellinger G, Sasaki AT, Locasale JW, Auld DS, Thomas CJ, Vander Heiden MG, Cantley LC.

Science. 2011 Dec 2;334(6060):1278-83. doi: 10.1126/science.1211485. Epub 2011 Nov 3.

29.

The SRC-associated protein CUB Domain-Containing Protein-1 regulates adhesion and motility.

Benes CH, Poulogiannis G, Cantley LC, Soltoff SP.

Oncogene. 2012 Feb 2;31(5):653-63. doi: 10.1038/onc.2011.262. Epub 2011 Jul 4.

30.

Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling.

Yu Y, Yoon SO, Poulogiannis G, Yang Q, Ma XM, Villén J, Kubica N, Hoffman GR, Cantley LC, Gygi SP, Blenis J.

Science. 2011 Jun 10;332(6035):1322-6. doi: 10.1126/science.1199484.

31.

Synergism between K-rasVal12 and mutant Apc accelerates murine large intestinal tumourigenesis.

Luo F, Poulogiannis G, Ye H, Hamoudi R, Arends MJ.

Oncol Rep. 2011 Jul;26(1):125-33. doi: 10.3892/or.2011.1288. Epub 2011 Apr 29.

PMID:
21573497
32.

Mutant K-ras promotes carcinogen-induced murine colorectal tumourigenesis, but does not alter tumour chromosome stability.

Luo F, Poulogiannis G, Ye H, Hamoudi R, Zhang W, Dong G, Arends MJ.

J Pathol. 2011 Feb;223(3):390-9. doi: 10.1002/path.2790. Epub 2010 Nov 11.

PMID:
21171084
33.

PARK2 deletions occur frequently in sporadic colorectal cancer and accelerate adenoma development in Apc mutant mice.

Poulogiannis G, McIntyre RE, Dimitriadi M, Apps JR, Wilson CH, Ichimura K, Luo F, Cantley LC, Wyllie AH, Adams DJ, Arends MJ.

Proc Natl Acad Sci U S A. 2010 Aug 24;107(34):15145-50. doi: 10.1073/pnas.1009941107. Epub 2010 Aug 9.

34.

A constitutively activated form of the p110beta isoform of PI3-kinase induces prostatic intraepithelial neoplasia in mice.

Lee SH, Poulogiannis G, Pyne S, Jia S, Zou L, Signoretti S, Loda M, Cantley LC, Roberts TM.

Proc Natl Acad Sci U S A. 2010 Jun 15;107(24):11002-7. doi: 10.1073/pnas.1005642107. Epub 2010 Jun 1.

35.

DNA mismatch repair deficiency in sporadic colorectal cancer and Lynch syndrome.

Poulogiannis G, Frayling IM, Arends MJ.

Histopathology. 2010 Jan;56(2):167-79. doi: 10.1111/j.1365-2559.2009.03392.x. Review.

PMID:
20102395
36.

K-ras exon 4A has a tumour suppressor effect on carcinogen-induced murine colonic adenoma formation.

Luo F, Ye H, Hamoudi R, Dong G, Zhang W, Patek CE, Poulogiannis G, Arends MJ.

J Pathol. 2010 Apr;220(5):542-50. doi: 10.1002/path.2672.

PMID:
20087880
37.

Prognostic relevance of DNA copy number changes in colorectal cancer.

Poulogiannis G, Ichimura K, Hamoudi RA, Luo F, Leung SY, Yuen ST, Harrison DJ, Wyllie AH, Arends MJ.

J Pathol. 2010 Feb;220(3):338-47. doi: 10.1002/path.2640.

PMID:
19911421
38.

Mutated K-ras(Asp12) promotes tumourigenesis in Apc(Min) mice more in the large than the small intestines, with synergistic effects between K-ras and Wnt pathways.

Luo F, Brooks DG, Ye H, Hamoudi R, Poulogiannis G, Patek CE, Winton DJ, Arends MJ.

Int J Exp Pathol. 2009 Oct;90(5):558-74. doi: 10.1111/j.1365-2613.2009.00667.x.

39.

p53-independent mechanisms regulate the P2-MDM2 promoter in adult astrocytic tumours.

Dimitriadi M, Poulogiannis G, Liu L, Bäcklund LM, Pearson DM, Ichimura K, Collins VP.

Br J Cancer. 2008 Oct 7;99(7):1144-52. doi: 10.1038/sj.bjc.6604643. Epub 2008 Sep 9.

40.

Conditional expression of mutated K-ras accelerates intestinal tumorigenesis in Msh2-deficient mice.

Luo F, Brooks DG, Ye H, Hamoudi R, Poulogiannis G, Patek CE, Winton DJ, Arends MJ.

Oncogene. 2007 Jun 28;26(30):4415-27. Epub 2007 Feb 5.

PMID:
17297472

Supplemental Content

Loading ...
Support Center